Harwood Feffer LLP Announces Investigation of Puma Biotechnology, Inc.
May 19, 2017
NEW YORK, May 19, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Puma Biotechnology, Inc. ("Puma" or the "Company") (NASDAQ: PBYI), concerning whether the board has breached its fiduciary duties to shareholders.
Puma's 2015 Form 10-K disclosed that: "Based on pre-clinical studies and clinical trials to date, we believe that neratinib may offer an advantage over existing treatments that are used in the treatment of patients with HER2-positive metastatic breast cancer."
On May 4, 2017, Puma announced the resignation of its Senior Vice President, Regulatory Affairs, effective as of May 15, 2017, less than two weeks before the FDA's scheduled review of neratinib. On May 5, 2017, Fox Business published an article reporting that a large number of patients taking neratinib suffered from severe side effects, posing a safety risk for the drug.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Puma shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Email: [email protected]
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP